Status:

RECRUITING

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Cancer-related Venous Thromboembolism

Eligibility:

All Genders

18+ years

Brief Summary

The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VT...

Detailed Description

If you agree to take part in this study, you will complete 2 questionnaires either at an already-scheduled clinic visit or over the phone at the time you join this study and then about 30 days, 3 mont...

Eligibility Criteria

Inclusion

  • Adult (≥ 18 years) female or male subjects.
  • Confirmed symptomatic proximal or distal lower extremity deep venous thrombosis with or without pulmonary embolism or other venous thromboses. For a symptomatic lower extremity deep venous thrombosis confirmed by compression ultrasonography, venography, or specific computerized tomography (CT) venography, or a thrombus detected in the iliac veins on an abdominal or pelvic CT. For symptomatic pulmonary embolism confirmed by computerized tomographic pulmonary angiography, ventilation perfusion scan, or catheter pulmonary angiography.
  • Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either active or diagnosed within 2 years prior to VTE. The diagnosis of cancer must be objectively documented by histopathologic diagnosis.
  • Intention for long-term treatment (at least 3 months) with anticoagulation.
  • Participants will be enrolled in the study within the first 5 days from initiation of anticoagulation.
  • Able to provide informed consent and complete study survey tools
  • Able to read and speak English.

Exclusion

  • Indication for anticoagulation other than cancer-related VTE.
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status of 4 at the time of study enrollment.
  • Life expectancy \< 3 months.
  • Isolated pulmonary embolism, or isolated upper extremity deep venous thrombosis, or isolated splanchnic venous thrombosis, or isolated cerebral venous thrombosis confirmed by compression ultrasonography, venography, or CT.

Key Trial Info

Start Date :

January 12 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

260 Patients enrolled

Trial Details

Trial ID

NCT03407469

Start Date

January 12 2018

End Date

December 31 2026

Last Update

November 18 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

2

Fundacion Valle del Lili

Cali, Colombia

3

Hospital Clinic

Barcelona, Carrer de Villarroel, 170, Spain, 08036

4

Hospital German Trias i Pujol

Barcelona, Spain, 08916